Familial Chylomicronemia Syndrome Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Familial Chylomicronemia Syndrome Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Familial Chylomicronemia Syndrome Market Share @ Familial Chylomicronemia Syndrome Market Outlook- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Familial Chylomicronemia Syndrome Market Report
• In April 2025, Arrowhead Pharmaceuticals announced AROAPOC3-3001 study is to evaluate the efficacy and safety of ARO-APOC3 plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.
• In January 2025, the FDA accepted a new drug application (NDA) for Arrowhead Pharmaceuticals' plozasiran, following the approval of the first treatment for familial chylomicronemia syndrome (FCS) a month earlier.
• As per DelveInsight's estimates, in 2022 theUS alone accounted for 65% of diagnosed prevalent FCS cases. The diagnosed prevalence of FCS is estimated to increase during the forecast period (2023-2034). The potential increase could be due to improved awareness, genetic predisposition, lifestyle changes, obesity rates, improved survival, shifting demographics, and environmental factors.
• Among the 7MM, EU4 and the UK accounted for nearly 23% diagnosed prevalent cases of Familial Chylomicronemia Syndrome (FCS) in 2022.
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of FCS, with nearly 135 cases, followed by the France and the UK in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In Japan, there were around 4,886k diagnosed prevalent cases of FCS in 2022. These cases are expected to increase at a significant CAGR.
• Age-specific diagnosed prevalent cases of Familial Chylomicronemia Syndrome (FCS) were distributed in two age groups 0-17 years and 18 years and above.
• The highest proportion of FCS cases was estimated in the 0-17 years. FCS has been observed across all ages, making age one of the major factors for this condition. While understanding this indication and analyzing the various research papers, we observed that FCS cases are most commonly diagnosed in the younger population (infants and younger adults).
• The leading Familial Chylomicronemia Syndrome Companies such as Ionis Pharmaceuticals Inc., Akcea Therapeutics, Novartis Pharmaceuticals, Arrowhead Pharmaceuticals, UniQure Biopharma B.V., and others.
• Promising Familial Chylomicronemia Syndrome Pipeline Therapies such as ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, and others.

Stay ahead in the Familial Chylomicronemia Syndrome Therapeutics Market with DelveInsight's Strategic Report @ Familial Chylomicronemia Syndrome Market Outlook- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Familial Chylomicronemia Syndrome Epidemiology Segmentation in the 7MM
• Total Familial Chylomicronemia Syndrome Prevalent Cases
• Total Familial Chylomicronemia Syndrome Diagnosed Prevalent Cases
• Familial Chylomicronemia Syndrome Age-specific Diagnosed Prevalent Cases
• Familial Chylomicronemia Syndrome Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Familial Chylomicronemia Syndrome Epidemiology trends @ Familial Chylomicronemia Syndrome Prevalence- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Familial Chylomicronemia Syndrome Marketed Drugs
• WAYLIVRA (volanesorsen): Akcea Therapeutics Ireland Limited/ Ionis Pharmaceuticals
WAYLIVRA (volanesorsen) is a self-administered SC injection with a prefilled syringe with a dosage for one-time use. In February 2019, the European Medicines Agency (EMA) gave conditional marketing authorization for the drug for patients with confirmed FCS at high risk of pancreatitis. There is an inadequate response to TG reduction therapy.

Familial Chylomicronemia Syndrome Emerging Drugs
• Olezarsen: Ionis Pharmaceuticals
Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of Apoc-III in the liver. In January 2023, Ionis Pharmaceuticals, Inc. received FTD from the US FDA for olezarsen to treat FCS. Olezarsen is patent protected in the US and Europe until at least 2034. Olezarsen is far ahead in its clinical development and may face competition with ARO-APOC3. WAYLIVRA is another drug approved in Europe for FCS, which will compete with Olezarsen in capturing the market. The clinical trials ongoing for Olezarsen have not yet produced concrete results to predict its future.

To learn more about Familial Chylomicronemia Syndrome Treatment guidelines, visit @ Familial Chylomicronemia Syndrome Treatment Market Landscape- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Familial Chylomicronemia Syndrome Drugs Market Insights
The available treatment choices for FCS can be separated into managing acute crises related to pancreatitis and chronic management of hypertriglyceridemia to reduce the risk of future episodes. Current pharmacological treatment options for patients suffering from FCS are fibrates, niacin, omega-3, and statins. However, in severely Interfered cases, these are often ineffective in lowering TG levels. The replacement of LPL with genetic replacement therapy is a hopeful treatment choice. One example of gene replacement therapy is the GLYBERA (alipogene tiparvovec). GLYBERA was the first gene therapy approved for the management of FCS. GLYBERA was administered by a series of intramuscular injections. However, this therapy was pulled from the market in 2017 due to poor commercial prospects and uncertainties about reimbursement.

Familial Chylomicronemia Syndrome Market Outlook
There is a lack of approved therapies for FCS in the market. Currently, no drug is approved by the United States FDA for managing FCS. Likewise, no therapy is approved in Japan as well. However, the EMA granted marketing authorization to WAYLIVRA (Volanesorsen) in the EU in May 2019. The drug has also been granted ODD by the US FDA and EMA but failed to get approval in the US. As per the ClinicalTrials.gov and additional secondary domain searches, the pipeline of FCS is not very robust. Not many companies have taken the initiative to meet the high medical requirement of this condition. But contrary to this, companies like Akcea Therapeutics, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals stepped into this field.

Learn more about the FDA-approved drugs for Familial Chylomicronemia Syndrome @ Drugs for Familial Chylomicronemia Syndrome Treatment- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Familial Chylomicronemia Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Familial Chylomicronemia Syndrome Companies- Ionis Pharmaceuticals Inc., Akcea Therapeutics, Novartis Pharmaceuticals, Arrowhead Pharmaceuticals, UniQure Biopharma B.V., and others.
• Familial Chylomicronemia Syndrome Pipeline Therapies- ARO-APOC3, VSA001 injection, Olezarsen, LCQ908, AKCEA-ANGPTL3-LRx, Volanesorsen, and others.
• Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome Market Drivers and Barriers
• Familial Chylomicronemia Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives, Familial Chylomicronemia Syndrome Clinical Trials

Discover more about Familial Chylomicronemia Syndrome Drugs in development @ Familial Chylomicronemia Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1 Key Insights
2 Familial Chylomicronemia Syndrome Market Report Introduction
3 Familial Chylomicronemia Syndrome Market Overview at a Glance
4 Familial Chylomicronemia Syndrome Epidemiology and Market Methodology
5 Executive Summary of Familial Chylomicronemia Syndrome (FCS)
6 Key Events
7 Disease Background and Overview Familial Chylomicronemia Syndrome (FCS)
8 Epidemiology and Patient Population of Familial Chylomicronemia Syndrome (FCS)
9 Patient Journey
10 Familial Chylomicronemia Syndrome Marketed Drugs
11 Familial Chylomicronemia Syndrome Emerging Drugs
12 Familial Chylomicronemia Syndrome (FCS): Seven Major Market Analysis
13 Familial Chylomicronemia Syndrome SWOT Analysis
14 Familial Chylomicronemia Syndrome Unmet Needs
15 Key Opinion Leaders' Views
16 Familial Chylomicronemia Syndrome Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of Top Selling Market Research Reports in 2025

Pulmonary emphysema market- https://www.delveinsight.com/report-store/pulmonary-emphysema-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac implantable electronic devices market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
HIP Replacement devices market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
LY3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Sepsis market_ https://www.delveinsight.com/report-store/sepsis-market-insight
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Coronary stents market- https://www.delveinsight.com/report-store/stents-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
India:- +91-9650213330

This release was published on openPR.